News related to Rilutek (Riluzole) and/or conditions it is approved for
Growth Hormone Did Not Help ALS Patients, Study
Source: Clinical Trials / Drug Trials News From Medical News Today [2008.11.25]
A growth hormone that an earlier study had suggested might be effective, showed no benefit compared to placebo in treating patients with amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, according to a new study performed by researchers in the United States. The research was conducted by lead author Dr Eric J Sorenson, of the Mayo Clinic in Rochester, Maine, USA, and colleagues, and was published in the 25 November issue of the journal Neurology.
Patients With ALS Do Not Benefit From Growth Hormone
Source: Multiple Sclerosis News From Medical News Today [2008.11.25]
A growth hormone that had shown some promise for treating people with amyotrophic lateral sclerosis (ALS) showed no benefit in a new study published in the November 25, 2008, issue of Neurology, the medical journal of the American Academy of Neurology. Two previous, shorter studies using growth hormone insulin-like growth factor-1, or IGF-1, to treat ALS had conflicting results.
Growth Hormones Again Disappoint
Source: MedPage Today Endocrinology [2008.11.24]
ROCHESTER, Minn. (MedPage Today) -- Patients with amyotrophic lateral sclerosis (ALS) saw no slowing in the progression of muscle weakness after injections of growth hormones, researchers found.
Neurons Derived From Embryonic Stem Cells Restore Muscle Function After Injury
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.11.20]
Dalhousie Medical School researchers have discovered that embryonic stem cells may play a critical role in helping people with nerve damage and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), regain muscular strength. Motor neurons reside in the spinal cord and control limb movements by enabling muscles to contract. Diseases like ALS cause them to degenerate, resulting in muscle weakness, atrophy, and eventual paralysis.
Q Therapeutics And Johns Hopkins Researchers Collaborate On Study Of Human Neural Glial Cells In Treatment Of ALS
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.10.22]
Q Therapeutics, Inc., announced today that studies are underway with Nicholas Maragakis, MD, and his research team at Johns Hopkins University to build on recent results showing that glial progenitor cells (GRPs) have a therapeutic benefit in a model of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. Results of the initial Johns Hopkins studies appear this week in Nature Neuroscience.
Prize4Life Launches $1 Million Prize For Finding Novel Treatment Candidates For ALS
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.10.22]
Prize4Life, a non-profit organization, today launched its latest prize, a one million dollar ($1M) award for finding a treatment candidate that reliably and significantly increases the lifespan in mouse models of ALS (amyotrophic lateral sclerosis), commonly known in the US as Lou Gehrig's disease. This prize, called the "Avi Kremer ALS Treatment Prize," is open to all interested researchers worldwide with the goal of accelerating the discovery of treatments and cures for ALS.
Stem Cells May Act As "Trojan Horse" To Deliver Gene Therapy To Injured Central Nervous System
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.10.14]
Amyotrophic lateral sclerosis (ALS) researchers at The Methodist Hospital in Houston have shown that transplanted bone marrow stem cells can attach themselves to injured areas in the brain or spinal cord, possibly providing a way to deliver future gene therapy. According to Dr. Stanley H. Appel's study published in the Oct.
Aeolus Pharmaceuticals Announces Initiation Of Multiple Dose Study Of AEOL 10150 In A Patient With ALS
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.10.02]
Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today that it has initiated a follow-on Phase I open label compassionate use multiple dose study of AEOL 10150 in a patient diagnosed with progressive and debilitating amyotrophic lateral sclerosis, also referred to as ALS or Lou Gehrig's disease. The study is being conducted at UCLA by Martina Wiedau-Pazos, M.D., and is designed to evaluate the safety and efficacy of AEOL 10150 in an ALS patient over an extended period of time.
Statins Not Linked To Higher Risk Of ALS Says FDA
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.09.30]
A new analysis by the US Food and Drug Administration (FDA) of data from over 40 clinical trials did not show a link between statins, drugs used to lower cholesterol, and higher risk of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as "Lou Gehrig's Disease". The FDA said there is no need to change prescribing practice.
Mechanism Uncovered Of Action Of Antibiotic Able To Reduce Neuronal Cell Death In Brain
Source: Huntingtons Disease News From Medical News Today [2008.05.12]
Research Highlights: Mechanism of action of compound found to induce neurotransmitter activity in brain cells The findings may lead researchers to develop potential novel therapies to treat Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease,
|
